Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EPS (Weighted Average and Diluted) (2016 - 2025)

IGC Pharma has reported EPS (Weighted Average and Diluted) over the past 11 years, most recently at -$0.02 for Q3 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed 0.0% to -$0.02 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$0.07 through Sep 2025, up 61.11% year-over-year, with the annual reading at -$0.09 for FY2025, 59.09% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.02 for Q3 2025 at IGC Pharma, roughly flat from -$0.02 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.01 in Q1 2025 and troughed at -$0.09 in Q4 2023.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.02 (2024), against an average of -$0.03.
  • Year-over-year, EPS (Weighted Average and Diluted) soared 77.78% in 2024 and then changed 0.0% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.09 in 2023, then skyrocketed by 77.78% to -$0.02 in 2024, then changed by 0.0% to -$0.02 in 2025.
  • Per Business Quant, the three most recent readings for IGC's EPS (Weighted Average and Diluted) are -$0.02 (Q3 2025), -$0.02 (Q2 2025), and -$0.01 (Q1 2025).